Cure rate of low-risk superficial basal cell carcinoma treated with topical 5-fluorouracil
Background: Basal cell carcinoma (BCC) is the most common cancer in the world making this condition a public health issue. Superficial BCC (sBCC) is a subtype with indolent behavior. The gold standard treatment is the surgical resection, however, sBCC can be treated with more cost-effective noninv...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Asociación Colombiana de Dermatología y Cirugía Dermatológica
2024-07-01
|
| Series: | Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica |
| Subjects: | |
| Online Access: | https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1834 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Basal cell carcinoma (BCC) is the most common cancer in the world making this condition a public health issue. Superficial BCC (sBCC) is a subtype with indolent behavior. The gold standard treatment is the surgical resection, however, sBCC can be treated with more cost-effective noninvasive therapies such as 5% 5-Fluorouracil (5-FU). The objective of this study was to evaluate the clinical cure rate, tolerability and satisfaction levels on patients featured intermediate pigmented skin in the treatment of low-risk superficial basal cell carcinoma with topical 5% 5-FU.
Methods: A prospective case series study was conducted between June 2014 and August 2018 at the dermatology service of Hospital de San José in Bogotá, Colombia with histologically-proven superficial BCC lesions. Lesions were treated with topical 5% 5-FU twice daily for up to 8 weeks. A follow-up evaluation was conducted at weeks four and eight during treatment. Follow-up was planned to be conducted every three months.
Results: The study included 19 patients with 23 biopsy-proven sBCC lesions. Twenty-two lesions completed treatment with 5% 5-FU cream. The follow-up period ranged between 7 and 48 months and the median follow-up time was 38 months (IQR 21-48). All study patients featured intermediate or higher pigmented skin. Clinical cure was achieved in 95.45% of treated lesions.
Conclusions: The efficacy rate of 5% 5-FU for 8 weeks treatment for sBCC located in intermediate and low-risk areas was 95% offering high levels of patient satisfaction with an outstanding tolerability profile.
|
|---|---|
| ISSN: | 1657-0448 2590-843X |